Bio Techne Corp Stock Net Asset
| TE1 Stock | 45.00 0.20 0.44% |
Bio Techne's fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting Bio Stock price.
Bio |
Bio Techne Corp Company Net Asset Analysis
Bio Techne's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Bio Techne Net Asset | 2.29 B |
Most of Bio Techne's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bio Techne Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Based on the recorded statements, Bio Techne Corp has a Net Asset of 2.29 B. This is much higher than that of the sector and significantly higher than that of the Net Asset industry. The net asset for all Germany stocks is notably lower than that of the firm.
Bio Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bio Techne's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bio Techne could also be used in its relative valuation, which is a method of valuing Bio Techne by comparing valuation metrics of similar companies.Bio Techne is currently under evaluation in net asset category among its peers.
Bio Fundamentals
| Current Valuation | 13.06 B | |||
| Price To Book | 7.56 X | |||
| Price To Sales | 12.34 X | |||
| Revenue | 1.11 B | |||
| EBITDA | 413.76 M | |||
| Net Income | 272.05 M | |||
| Total Debt | 243.41 M | |||
| Cash Flow From Operations | 325.27 M | |||
| Price To Earnings To Growth | 1.11 X | |||
| Market Capitalization | 16.22 B | |||
| Total Asset | 2.29 B | |||
| Z Score | 39.6 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 2.29 B |
About Bio Techne Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bio Techne Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Techne using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Techne Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Bio Stock Analysis
When running Bio Techne's price analysis, check to measure Bio Techne's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Techne is operating at the current time. Most of Bio Techne's value examination focuses on studying past and present price action to predict the probability of Bio Techne's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Techne's price. Additionally, you may evaluate how the addition of Bio Techne to your portfolios can decrease your overall portfolio volatility.